Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 6;11(4):ofae127.
doi: 10.1093/ofid/ofae127. eCollection 2024 Apr.

Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences

Affiliations

Characteristics of Patients With Initial Clostridioides difficile Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences

Alice Y Guh et al. Open Forum Infect Dis. .

Abstract

Background: Because interventions are available to prevent further recurrence in patients with recurrent Clostridioides difficile infection (rCDI), we identified predictors of multiple rCDI (mrCDI) in adults at the time of presentation with initial CDI (iCDI).

Methods: iCDI was defined as a positive C difficile test in any clinical setting during January 2018-August 2019 in a person aged ≥18 years with no known prior positive test. rCDI was defined as a positive test ≥14 days from the previous positive test within 180 days after iCDI; mrCDI was defined as ≥2 rCDI. We performed multivariable logistic regression analysis.

Results: Of 18 829 patients with iCDI, 882 (4.7%) had mrCDI; 437 with mrCDI and 7484 without mrCDI had full chart reviews. A higher proportion of patients with mrCDI than without mrCDI were aged ≥65 years (57.2% vs 40.7%; P < .0001) and had healthcare (59.1% vs 46.9%; P < .0001) and antibiotic (77.3% vs 67.3%; P < .0001) exposures in the 12 weeks preceding iCDI. In multivariable analysis, age ≥65 years (adjusted odds ratio [aOR], 1.91; 95% confidence interval [CI], 1.55-2.35), chronic hemodialysis (aOR, 2.28; 95% CI, 1.48-3.51), hospitalization (aOR, 1.64; 95% CI, 1.33-2.01), and nitrofurantoin use (aOR, 1.95; 95% CI, 1.18-3.23) in the 12 weeks preceding iCDI were associated with mrCDI.

Conclusions: Patients with iCDI who are older, on hemodialysis, or had recent hospitalization or nitrofurantoin use had increased risk of mrCDI and may benefit from early use of adjunctive therapy to prevent mrCDI. If confirmed, these findings could aid in clinical decision making and interventional study designs.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. D. N. G. is a consultant for Destiny Pharma, Sebela Pharma, and AstraZeneca and holds technology for treatment of CDI licensed to Destiny Pharma. G. D. had received a grant from Pfizer. All other authors report no potential conflicts.

Figures

Figure 1.
Figure 1.
Flow diagram depicting the selection of patients with initial Clostridioides difficile infection for chart review and inclusion in the analysis. Abbreviations: CDI, Clostridioides difficile infection; EIP, Emerging Infections Program. aPatients with community-onset CDI who underwent a full chart review were less likely than those without a chart review to be community-associated (71.0% vs 93.3%; P = .004), but there were no differences in the proportion who were female (P = .10), aged ≥65 y (P = .93), or who had multiple recurrent CDI (P = 1.00) or died within 180 d of initial CDI (P = .69). bPatients with healthcare facility-onset CDI (ie, hospital-onset or long-term care facility onset CDI) who had a full chart review were less likely than those without a chart review to be long-term care facility-onset (32.7% vs 38.5%; P = .004), but there were no differences in the proportion who were female (P = .19), aged ≥65 y (P = .32), or who had multiple recurrent CDI (P = .51), or died within 180 d of initial CDI (P = .48).

References

    1. Guh AY, Mu Y, Winston LG, et al. . Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 2020; 382:1320–30. - PMC - PubMed
    1. Tsigrelis C. Recurrent Clostridioides difficile infection: recognition, management, prevention. Cleve Clin J Med 2020; 87:347–59. - PubMed
    1. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER. Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect 2015; 21:164–70. - PubMed
    1. Olsen MA, Yan Y, Reske KA, Zilberberg M, Dubberke ER. Impact of Clostridium difficile recurrence on hospital readmissions. Am J Infect Control 2015; 43:318–22. - PubMed
    1. Zhang D, Prabhu VS, Marcella SW. Attributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile infection in the United States. Clin Infect Dis 2018; 66:1326–32. - PMC - PubMed